Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide: an old sedative-hypnotic with anticancer activity?

G Gasparini1, A Morabito, E Magnani

  • 1Division of Medical Oncology, Azienda Complesso Ospedaliero San Filippo Neri, Via Martinotti 20, 00135 Rome, Italy. gasparini.oncology@tiscalinet.it

Current Opinion in Investigational Drugs (London, England : 2000)
|November 23, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

ItaLynch: an ongoing Italian study to evaluate the feasibility of mainstreaming the diagnosis of Lynch syndrome in colorectal cancer patients.

ESMO gastrointestinal oncology·2026
Same author

Fetal treatment of sacrococcygeal teratoma: state of the art.

Frontiers in pediatrics·2025
Same author

Corrigendum to "Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials": [ESMO Open 9 (2024) 102941].

ESMO open·2024
Same author

Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials.

ESMO open·2024
Same author

Corrigendum: Gut and spleen anomalies associated with DYRK1A syndrome.

Frontiers in pediatrics·2024
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Thalidomide, once known for birth defects, shows promise in treating cancers like multiple myeloma and glioblastoma. Further research is needed to confirm its effectiveness and potential in cancer-related cachexia.

Area of Science:

  • Pharmacology
  • Oncology
  • Teratology

Background:

  • Thalidomide, a glutamic acid derivative, historically caused severe teratogenic effects.
  • Despite its past, thalidomide exhibits sedative-hypnotic and potential antitumor activities.
  • Understanding its mechanisms is crucial for exploring new therapeutic applications.

Purpose of the Study:

  • To review the mechanisms behind thalidomide's teratogenicity.
  • To explore emerging therapeutic indications for thalidomide, particularly in oncology.
  • To synthesize current evidence on thalidomide's efficacy in various cancers.

Main Methods:

  • Literature review of published studies on thalidomide.
  • Analysis of proposed mechanisms for antitumor activity.

Related Experiment Videos

  • Evaluation of clinical data regarding thalidomide's application in cancer treatment.

    • Main Results:

    • Thalidomide demonstrates clinical promise in multiple myeloma, glioblastoma multiforme, and renal cell cancer.
    • Potential benefits in managing cancer-related cachexia are suggested, requiring further investigation.
    • Current data supports thalidomide's emerging role in specific oncological settings.

    Conclusions:

    • Thalidomide presents a complex profile with historical teratogenic risks and current therapeutic potential in oncology.
    • Further well-designed, randomized studies are essential to validate its antitumor indications.
    • Thalidomide warrants continued investigation for its application in treating various cancers and associated conditions.